Seebri Breezhaler 44 micrograms inhalation powder

Seebri Breezhaler is a maintenance bronchodilator treatment used to relieve symptoms of chronic obstructive pulmonary disease (COPD). It contains the active ingredient glycopyrronium bromide, which belongs to a group of medicines called long-acting muscarinic antagonists (LAMAs). The product is designed to be inhaled using a specific 'Breezhaler' device, which releases the powder from a hard capsule.

The brand was developed and brought to market by Novartis, a leading global pharmaceutical company based in Switzerland. Novartis holds the primary patents and marketing authorizations for the Breezhaler device and its associated medications. Manufacturing takes place at various highly regulated pharmaceutical facilities across Europe and other regions to meet global demand, with significant production often occurring in Switzerland or Ireland.

As of the forecast for 2026, the brand remains under the ultimate ownership of Novartis AG. The company continues to invest in respiratory care and the Breezhaler platform as part of its core innovative medicines portfolio.